The Three Most Important Drugs in Gilead's Pipeline

Published: Dec 08, 2015

Although blue-chip biotech stock Gilead Sciences (NASDAQ:GILD) has had a bit of an up and down year, it's still sitting on a year-to-date gain of nearly 10%.

The catalyst behind Gilead's ongoing strength has been its hepatitis C franchise, headlined by Sovaldi and Harvoni, the company's once-daily HCV pills. These drugs have made an incredible difference in the lives of HCV patients, with cure rates typically above 90%, and relatively minimal side effects compared to the flu-like symptoms, anemia, and rashes which often accompanied the previous standard of care.

Back to news